Jones, J R <br/><br/>
Second malignancies in the context of lenalidomide treatment: an analysis of 2732 myeloma patients enrolled to the Myeloma XI trial.  [electronic resource] 

 -  Blood cancer journal  12 2016 
 - e506 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial 
<br/><br/><label>ISSN: </label>2044-5385 
<br/><br/><label>Standard No.: </label>10.1038/bcj.2016.114  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Bortezomib--administration & dosage<br/>Disease-Free Survival<br/>Female<br/>Humans<br/>Hydroxamic Acids<br/>Kaplan-Meier Estimate<br/>Lenalidomide<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Neoplasms, Second Primary--drug therapy<br/>Oligopeptides--administration & dosage<br/>Risk Factors<br/>Thalidomide--administration & dosage<br/>Vorinostat